New treatment strategies for proliferative lupus nephritis: keep children in mind! (Q36915693)

17 August 2017

1 reference

title

New treatment strategies for proliferative lupus nephritis: keep children in mind! (English)

1 reference

17 August 2017

1 reference

S Fargue

1 reference

17 August 2017

B Ranchin

1 reference

17 August 2017

publication date

1 January 2007

1 reference

17 August 2017

1 reference

17 August 2017

1 reference

17 August 2017

1 reference

17 August 2017

page(s)

684-691

1 reference

Lupus nephritis in childhood: a review of 53 patients followed at a single center

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0961203307079810

Short-term outcomes of severe lupus nephritis in a cohort of predominantly African-American children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307079810

Adolescent development and SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307079810

Evidence for the Superiority of Immunosuppressive Drugs and Prednisone over Prednisone Alone in Lupus Nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307079810

Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307079810

Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307079810

Effects of cyclophosphamide on the development of malignancy and on long‐term survival of patients with rheumatoid arthritis a 20‐year followup study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307079810

Disease outcomes and ovarian function of childhood-onset systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307079810

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307079810

Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307079810

Long-term treatment of lupus nephritis with cyclosporin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307079810

Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307079810

Clinical efficacy of cyclosporin a neoral in the treatment of paediatric lupus nephritis with heavy proteinuria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307079810

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307079810

An open study of B lymphocyte depletion in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307079810

Effective B cell depletion with rituximab in the treatment of autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307079810

Remission of refractory lupus nephritis with a protocol including rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307079810

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307079810

B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307079810

Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression: case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307079810

Rituximab: a promising therapy in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307079810

Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307079810

Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307079810

Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307079810

Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307079810

Sequential therapies for proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307079810

Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307079810

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307079810

Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307079810

Antiproteinuric effect of ARB in lupus nephritis patients with persistent proteinuria despite immunosuppressive therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307079810

Angiotensin-converting enzyme inhibition and angiotensin II antagonism in nondiabetic chronic nephropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307079810

Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307079810

Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307079810

A Randomized Pilot Trial Comparing Cyclosporine and Azathioprine for Maintenance Therapy in Diffuse Lupus Nephritis over Four Years

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307079810

21 January 2018

Identifiers

DOI

10.1177/0961203307079810

1 reference

17 August 2017

1 reference